Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C-Reference-Cited by-同舟云学术

Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

Published:2020-08-20 Issue:18 Volume:63 Page:10380-10395
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Guangyi¹,Dyatkina Natalia¹^ORCID,Prhavc Marija¹^ORCID,Williams Caroline¹,Serebryany Vladimir¹,Hu Yujian²,Huang Yongfei²,Wu Xiangyang²,Chen Tongqian³,Huang Wensheng³,Rajwanshi Vivek K.¹,Deval Jerome¹,Fung Amy¹,Jin Zhinan¹,Stoycheva Antitsa¹^ORCID,Shaw Kenneth¹,Gupta Kusum¹,Tam Yuen¹,Jekle Andreas¹,Smith David B.¹,Beigelman Leonid¹

Affiliation:

1. Janssen BioPharma, Inc., 260 E. Grand Avenue, South San Francisco, California 94080, United States

2. Department of Medicinal Chemistry, WuXi AppTec, Shanghai 200131, P. R. China

3. Pharmaron Beijing, Co. Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00935

Reference48 articles.

1. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org (accessed May 8, 2020).